Skip to content

Viviana Trezza

4 papers in the library · 697 citations · publishing 2005-2026

Papers

Sort Most recent Most cited

Classic psychedelics and autism spectrum disorder: preclinical evidence, mechanistic insights and unresolved challenges.

Neuroscience and Biobehavioral Reviews August 1, 2026 Fabrizio Ascone, Diletta Giangiacomo, Viviana Trezza

Classic psychedelics have re-emerged as compelling probes of neural plasticity, raising interest in their potential relevance for behavioral and circuit-level features associated with autism spectrum disorder (ASD). Although only a limited number of studies have examined these compounds in validated animal models of ASD, a growing body of preclinical work has investigated their effects on...

Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway

Neuropsychopharmacology February 13, 2026 Fabrizio Ascone, Valeria Buzzelli, Francesca Mottarlini et al. 2 citations

Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a synaptic disorder, FXS involves the loss of Fragile X messenger ribonucleoprotein 1 (FMRP), leading to abnormal dendrite development and immature dendritic spines. Serotonergic signaling, essential for neuronal development and circuit remodeling,...

Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome.

Psychopharmacology 2023 Valeria Buzzelli, Emilia Carbone, Antonia Manduca et al. 20 citations

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability (ID) and the leading monogenic cause of autism spectrum disorder (ASD). Serotonergic neurotransmission has a key role in the modulation of neuronal activity during development, and therefore, it has been hypothesized to be involved in ASD and co-occurring conditions including FXS. As serotonin is involved in...

Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

Proceedings of the National Academy of Sciences December 13, 2005 Gabriella Gobbi, Francis Rodriguez Bambico, Regina A. Mangieri et al. 675 citations

Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application. The active constituent of cannabis, delta9-tetrahydrocannabinol, acts by binding to brain CB1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of...